Targeted PI3K/AKT-hyperactivation induces cell death in chronic lymphocytic leukemia
- Veronika Ecker
- Martina Stumpf
- Lisa Brandmeier
- Tanja Neumayer
- Lisa Pfeuffer
- Thomas Engleitner
- Ingo Ringshausen
- Nina Nelson
- Manfred Jücker
- Stefan Wanninger
- Thorsten Zenz
- Clemens Wendtner
- Katrin Manske
- Katja Steiger
- Roland Rad
- Markus Müschen
- Jürgen Ruland
- Maike Buchner
Publication date
June 2021
DOI Publisher
Springer Science and Business Media LLC Journal
Nature CommunicationsAbstract
Current therapeutic approaches in chronic lymphocytic leukemia (CLL) focus on the suppression of PI3K/AKT signaling. Here, the authors show that CLL cells are vulnerable to hyperactivation of the PI3K/AKT signaling pathway and suggest this as a promising concept for CLL therapy
Add to ORKG